Form 4: 4D Molecular Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
David Kirn, See Remarks and a Director of 4D Molecular Therapeutics, Inc., sold 58,333 shares of common stock on October 5, 2026.
Summary
- Open-market sale: disposed of 58,061 Common Stock at $12.92 ($750,235) on October 5, 2026; holds 709,425 after (Direct).
- Open-market sale: disposed of 272 Common Stock at $13.61 ($3,702) on October 5, 2026; holds 709,153 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $753,937 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
David Kirn — Director, Officer (See Remarks)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-05 | Open-market sale | Common Stock | 58,061 | $13 | $750.2K | 709,425 |
| 2026-10-05 | Open-market sale | Common Stock | 272 | $14 | $3.7K | 709,153 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-05 | Open-market sale (58,061 shares) |
| 2026-10-05 | Open-market sale (272 shares) |
Keywords
insider transaction, Form 4, FDMT, 4D Molecular Therapeutics, Inc., bearish, David Kirn
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.